AnaptysBio (NASDAQ:ANAB) Earns “Buy” Rating from HC Wainwright

AnaptysBio (NASDAQ:ANAB)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $95.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 66.73% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Barclays lifted their target price on shares of AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Leerink Partners set a $90.00 price target on shares of AnaptysBio in a report on Friday, May 15th. Weiss Ratings restated a “sell (e+)” rating on shares of AnaptysBio in a research report on Friday, August 7th. Piper Sandler dropped their price objective on shares of AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Finally, UBS Group upped their target price on shares of AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $82.00.

AnaptysBio Stock Performance

AnaptysBio stock traded down $0.76 during midday trading on Monday, reaching $56.98. 29,706 shares of the stock were exchanged, compared to its average volume of 716,005. The company’s fifty day moving average is $58.56 and its 200-day moving average is $58.83. The firm has a market cap of $1.69 billion, a PE ratio of -52.76 and a beta of 0.72. AnaptysBio has a 52 week low of $11.40 and a 52 week high of $72.36.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently bought and sold shares of the business. Persistent Asset Partners Ltd bought a new stake in shares of AnaptysBio during the second quarter valued at approximately $39,000. Smartleaf Asset Management LLC lifted its position in AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares during the period. Larson Financial Group LLC lifted its position in AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its holdings in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.